Aganirsen demonstrates significant activity in two models of wet AMD.

The scholarly research reported in Investigative Ophthalmology & Visual Science, if confirmed in clinical trials, show unprecedented evidence that topical aganirsen is an innovative compound that may provide advantages over available drugs due to its topical delivery and different mode of action along with a fantastic efficacy and safety profile. A topical agent for retinal neovascular disease would revolutionize treatment, noted Eric Viaud, CEO of Gene Transmission.. Aganirsen demonstrates significant activity in two models of wet AMD, ischemic retinopathy Gene Signal, a business centered on developing innovative drugs to control angiogenesis based conditions, today announced the publication of data demonstrating the significant activity of aganirsen in two important types of retinal neovascular disease, wet age-related macular degeneration and ischemic retinopathy.Kaiser Health News, an unbiased news service editorially, is a scheduled program of the Kaiser Family Foundation, a nonpartisan health care policy research corporation unaffiliated with Kaiser Permanente.

Acetylon announces results from selective HDAC 1/2 inhibitor preclinical study on SCD and bT Acetylon Pharmaceuticals Inc., a leader in targeted epigenetic medication development and discovery for improved therapeutic outcomes, today announced results from a preclinical research of a selective histone deacetylase 1/2 inhibitor for the treating sickle cell disease and beta-thalassemia at the 54th Annual Getting together with of the American Society of Hematology , occurring in Atlanta, Georgia. The analysis results claim that selective inhibition of the epigenetic regulators of gene expression, HDACs 1 and 2, could represent a refined and targeted approach for the treating SCD and bT through the induction of disease-corrective fetal hemoglobin in human red bloodstream cell progenitors.